Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
National Institute of Neurological Disorders and Stroke (NINDS) · NCT00001248
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–120 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 3750
- US sites recruiting
- 1
- Study start
- July 23, 1992
- Record last updated
- September 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Studies performed under 89-N-0045 are designed to examine the natural history of multiple sclerosis (MS) using MRI and immunological measures. In addition to studying the natural history of untreated patients, the natural history of patients receiving approved disease-modifying therapies of MS will be examined. In both cohorts of patients levels of disease activity on MRI will be compared with immunological characteristics in order to help identify disease mechanism. Patients with either definite MS (based either on clinical or combined clinical and MRI criteria) or with an initial presentation of neurological dysfunction consistent with MS will be studied longitudinally by MRI. Disease activity on MRI will be assessed using several MRI measures of disease activity including the number of contrast enhancing lesions, the overall burden of disease, brain atrophy and measures to assess axonal damage. Patients will be assessed clinically and correlations between immunological and genetic factors and disease activity as seen clinically or by MRI will be studied.
A second cohort of patients starting the use of approved therapy will also be examined. Patients referred to NIH prior to beginning approved therapy will be assessed with a series of three monthly MRIs to determine the level of pretreatment disease activity. After beginning approved therapy under the direction of their private physician, patients will be followed similarly to the natural history cohort. Immunological and genetic findings will be accessed before and during therapy in order to help establish the mechanisms of action of the therapies and to identify mechanisms accounting for either a response or lack of response to therapy. Part of the collected samples willl be cryopreserved to provide respository for further studies focusing on detection of biomarkers indicative of disease state, disease stage or repsonse to therapies.
Additionally, a cohort of normal volunteers will be studied. The studies in the normal volunteers will be used to establish the most appropriate imaging sequences for studying normal white matter in MS patients using magnetization transfer (MT) imaging sequences for studying normal white matter in MS patients using magnetization transfer (MT) imaging and to provide normative immunological measures.
Conditions: Multiple Sclerosis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- One of the following:
- Affected participant with either a diagnosis of MS based on currently accepted diagnostic criteria, or imaging or clinical abnormalities associated with MS.
- Healthy volunteer.
- Age >=18
- Able to give informed consent.
EXCLUSION CRITERIA
An individual who meets any of the following criteria will be excluded from participation in this study:
- Contraindication to MRI at the time of initial enrollment (with the exception of pregnancy).
- Unwilling to allow coded samples to be processed offsite or unwilling to have coded samples used in other studies.
Recruiting US locations
National Institutes of Health Clinical Center
Bethesda, MD 20892
Site contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · 800-411-1222 · ccopr@nih.gov
Study contacts (from the official record)
- Jenifer E Dwyer · (301) 496-3825 · jenifer.dwyer@nih.gov
- Daniel S Reich, M.D. · (301) 496-1801 · reichds@ninds.nih.gov
Similar studies in Maryland
All neurology studies in Maryland →- RecruitingHealthy volunteersPhase 1
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
Suninflam Inc
- Location
- Bathesda, MD + 9 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1
First-in-Human Single and Multiple Dose of HL-400
Highlightll Pharmaceutical (USA) LLC
- Location
- Baltimore, MD
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
PRG Science & Technology Co., Ltd.
- Location
- Baltimore, MD
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
National Institute of Mental Health (NIMH)
- Location
- Bethesda, MD
- Eligibility basics
- Ages 50–100